NIKKEI 225
38,229.11 -44.99 (-0.12%) HANG SENG
18,963.68 +487.78 (+2.64%) CRUDE OIL
78.07 -0.19 (-0.24%) GOLD FUTURES
2,368.10 -6.90 (-0.29%) DOW
39,512.84 +837.14 (+2.16%) Bitcoin GBP
48,980.46 +339.03 (+0.70%)
Apogee Therapeutics, Inc. (APGE)
After hours:
| Previous close | 52.92 |
| Open | 56.10 |
| Bid | 52.98 x 300 |
| Ask | 53.38 x 100 |
| Day's range | 51.30 - 56.10 |
| 52-week range | 14.19 - 72.29 |
| Volume | |
| Avg. volume | 688,493 |
| Market cap | 3.11B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference
SAN FRANCISCO and WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, COPD, asthma and other inflammatory and immunology indications, today announced that Michael Henderson, M.D., Chief Executive Officer and Jane Pritchett Henderson, Chief Financial Officer, will participate in a fireside chat at the 2024 Bank of America Healthcare Conference on
- GlobeNewswire
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases
Preclinical data with APG808 demonstrate the potential for improved dosing over other treatment options in development, including the potential for dosing every six- or eight- weeks compared to dosing every two weeks for other biologics in development Second product candidate to enter the clinic following positive interim results from Phase 1 Healthy Volunteer Trial for APG777, which exceeded all of its trial objectives Interim subcutaneous safety and pharmacokinetic data from healthy volunteers
- GlobeNewswire
Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million
SAN FRANCISCO, Calif. and WALTHAM, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, asthma and other inflammatory and immunology indications (Apogee or the Company), today announced the closing of its previously announced upsized public offering of 7,790,321 shares of common stock, including the full e
